Clinical Trial Update: Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating everolimus plus rituximab in relapsed/refractory diffuse large B-cell lymphoma has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Afinitor (everolimus)
• Rituxan (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-10-27